[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.90.95. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Comments, Opinions, and Brief Case Reports
July 28, 2003

Should Diabetic Patients Treated Long-term With Sulfonylureas Be Switched to Nateglinide?

Arch Intern Med. 2003;163(14):1741. doi:10.1001/archinte.163.14.1741

Nateglinide, a rapidly acting insulinotrophic agent with a short duration of action, has been shown to selectively increase early insulin release in a glucose-sensitive manner. These properties have been demonstrated in vitro1 and in vivo2 in animals and in patients with type 2 diabetes mellitus.3 Nateglinide is indicated as monotherapy to lower the blood glucose levels in patients with type 2 diabetes whose hyperglycemia is not adequately controlled by diet and exercise alone and who have not been treated long-term with other antidiabetic agents.4

First Page Preview View Large
First page PDF preview
First page PDF preview
×